Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis
| Autor: | Olivier Casez, Serge Urbach, Delphine Loussouarn, Sylvain Lehmann, Mounerou Salou, Christophe Demattei, Giovanni Castelnovo, Valérie Rigau, Eric Thouvenot, Geoffrey Hinsinger, David Brassat, Philippe Marin, David Laplaud, Nathalie Galéotti, Joël Bockaert, William Camu, Nicolas Nabholz, Pierre Labauge |
|---|---|
| Přispěvatelé: | Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Service d'Ophtalmologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Guy de Chauliac, Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Pôle neurosciences [Hôpital de Purpan - Toulouse], CHU Toulouse [Toulouse], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Département de neurologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Proteomics Pathology medicine.medical_specialty Multiple Sclerosis [SDV]Life Sciences [q-bio] Quantitative proteomics Biology CHI3L1 White matter 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid Adipokines Lectins medicine Humans Chitinase-3-Like Protein 1 ComputingMilieux_MISCELLANEOUS 030304 developmental biology 0303 health sciences Clinically isolated syndrome Multiple sclerosis Chitinases Brain Middle Aged medicine.disease 3. Good health medicine.anatomical_structure Neurology Immunology Proteome Disease Progression Female Neurology (clinical) Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis Journal Multiple Sclerosis Journal, SAGE Publications, 2015, 21 (10), pp.1251-1261. ⟨10.1177/1352458514561906⟩ |
| ISSN: | 1352-4585 1477-0970 |
| Popis: | Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment. Objective: The objective of this paper is to identify cerebrospinal fluid (CSF) diagnostic biomarkers of MS using quantitative proteomics and to analyze their expression at different disease stages. Methods: We conducted differential analysis of the CSF proteome from control and relapsing–remitting MS (RRMS) patients followed by verification by ELISA of candidate biomarkers in CSF and serum in control, clinically isolated syndrome (CIS), RRMS and progressive MS (PMS) patients. Results: Twenty-two of the 527 quantified proteins exhibited different abundances in control and RRMS CSF. These include chitinase 3-like protein 1 (CHI3L1) and 2 (CHI3L2), which showed a strong expression in brain of MS patients, especially in astrocytes and microglial cells from white matter plaques. CSF and serum CHI3L1 levels increased with the disease stage and CIS patients with high CSF (>189 ng/ml) and serum (>33 ng/ml) CHI3L1 converted more rapidly to RRMS (log rank test, p < 0.05 and p < 0.001, respectively). In contrast, CSF CHI3L2 levels were lower in PMS than in RRMS patients. Accordingly, CSF CHI3L1/CHI3L2 ratio accurately discriminated PMS from RRMS. Conclusions: CSF CHI3L1 and CHI3L2 and serum CHI3L1 might help to define MS disease stage and have a prognostic value in CIS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|